67227-57-0

Basic information

• Product Name: 8-Chloro-2-(4-hydroxyphenyl)-4-azabicyclo[5.4.0]undeca-7,9,11-triene-9,10-diol methanesulphonate
• Synonyms: 6-CHLORO-2,3,4,5-TETRAHYDRO-1-(4-HYDROXYPHENYL)-1H-3-BENZAZEPINE-7,8-DIOL MESYLATE;CORLOPAM MESYLATE;FENOLDOPAM MESYLATE;6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-(p-hydroxyphenyl)-1H-3-benzazepinium methanesulphonate;Fenodopam mesylate;FENOLDOPAM METHANESULFONATE;FenoldopamMesylateC16H16C1N03.CH403S;8-Chloro-2-(4-hydroxyphenyl)-4-azabicyclo[5.4.0]undeca-7,9,11-triene-9,10-diol methanesulphonate
• CAS NO: 67227-57-0
• Molecular Formula: CH₄O₃S*C₁₆H₁₆ClNO₃
• Molecular Weight: 401.86
• EINECS: 266-612-7
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;CORLOPAM
• Mol File: 67227-57-0.mol
• Article Data: 3

Chemical Properties

• Melting Point: 274° (dec)
• Boiling Point: 522.6 °C at 760 mmHg
• Flash Point: 269.9 °C
• Appearance: white to tan/
• Density: 1.38g/cm3
• Vapor Pressure: 1.53E-11mmHg at 25°C
• Storage Temp.: room temp
• Solubility: DMSO: ≥15mg/mL at ~60°C
• CAS DataBase Reference: 8-Chloro-2-(4-hydroxyphenyl)-4-azabicyclo[5.4.0]undeca-7,9,11-triene-9,10-diol methanesulphonate(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Chloro-2-(4-hydroxyphenyl)-4-azabicyclo[5.4.0]undeca-7,9,11-triene-9,10-diol methanesulphonate(67227-57-0)
• EPA Substance Registry System: 8-Chloro-2-(4-hydroxyphenyl)-4-azabicyclo[5.4.0]undeca-7,9,11-triene-9,10-diol methanesulphonate(67227-57-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36-42/43
• Safety Statements: 22-26-36/37/39
• WGK Germany: 3
• Hazardous Substances Data: 67227-57-0(Hazardous Substances Data)

Usage

Description

Different sources of media describe the Description of 67227-57-0 differently. You can refer to the following data:
1. Fenoldopam, first approved in the Netherlands in 1992, ended by reaching its first market, the US, for the short-term management of severe hypertension, including malignant hypertension, in the hospital setting. Fenoldopam can be prepared in 3 steps from the corresponding phenethylamine and aryloxiran, the pivotal step being the cyclisation in benzazepine in acidic medium. Fenoldopam is a potent dopamine D1 receptor agonist acting peripherally to produce systemic vasodilation.As it does not cross the bloodbrain barrier, it does not exert significant central dopaminergic activity. Fenoldopam also interacts significantly with 5HT1c and 5HT2 receptors. In comparative trials with the most common drug used for this condition in Europe, Fenoldopam was found to be appreciably more potent than nifedipine. Furthermore, Fenoldopam is fast acting and maintains a long-lasting antihypertensive effect.
2. Fenoldopam is an agonist of dopamine D1A (D1R) and D1B (D5R) receptors (Kds = 17 and 11 nM, respectively). Fenoldopam is used to study the roles of these receptors, in cells and in vivo, and to alter hemodynamic properties, including hypertension, in animals.

Chemical Properties

White to Off-White Solid

Uses

Different sources of media describe the Uses of 67227-57-0 differently. You can refer to the following data:
1. antihypertensive, dopamine agonist
2. Fenoldopam mesylate may be used to study dopamine D1-mediated cell signaling.

Therapeutic Function

Antihypertensive

Biochem/physiol Actions

Fenoldopam mesylate (FM) is considered as an effective therapeutic agent to prevent the onset of postoperative AKI (PO-AKI). In healthy cats, FM can stimulate diuresis and be well-tolerated. This benzazepine-derivative is regional specific and does not cause cerebral vasodilation.

InChI:InChI=1/C16H16ClNO3.CH4O3S/c17-15-11-5-6-18-8-13(9-1-3-10(19)4-2-9)12(11)7-14(20)16(15)21;1-5(2,3)4/h1-4,7,13,18-21H,5-6,8H2;1H3,(H,2,3,4)

Upstream product

• 75-75-2 methanesulfonic acid 
• 67227-56-9 fenoldopam 

Downstream Products

• 100166-76-5 (E)-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-(3-phenylallyl)-3-benzazepine-7,8-diol 

Relevant articles and documents

CRYSTALLINE FORMS FENOLDOPAM MESYLATE

The invention provides new crystalline forms of fenoldopam mesylate, i.e. fenoldopam mesylate Type I, fenoldopam mesylate Type III, fenoldopam mesylate Type V, and fenoldopam mesylate Type VI, methods of preparing the crystalline forms, and pharmaceutical compositions comprising the fenoldopam mesylate crystalline forms of the invention.

Solid oral preparation containing a pyrrolidine derivative with a catechol group

An oral solid preparation comprising an organic acid or its salt and a catechol compound. The catechol compound is, for example, a pyrrolidine derivative having a catechol group of the following general formula (I). It exhibits an improved absorbability in vivo. STR1